LinkedInXFacebook
Subscribe
Orthopedics This Week
  • My Feed
  • |Posts
  • |Events
  • |MSK Innovations
  • |Power Rankings
  • |Masterclasses
  • |Technology Awards
  • Press Releases
  • |Advertising
  • |Job Board
  • Spine
  • ◆Joints
  • ◆Upper Extremities
  • ◆Foot & Ankle
  • ◆Sports Medicine
  • ◆Pain Mgmt
  • ◆Trauma
  • ◆Biologics
  • ◆Technology
  • ◆People
  • ◆Company News
  • ◆Legal & Regulatory
Home/Spine/C7 or T1/T2: No Difference in Adjacent Segment Reop Rates
Spine

C7 or T1/T2: No Difference in Adjacent Segment Reop Rates

January 19, 2022 2 min read Premium comments

Advertisement

Secondary#adjacentsegmentdisease#posteriorcervicalfusions#reoperationrates

Researchers found no difference in reoperation rates for adjacent segment disease in posterior cervical fusions stopping at -C7 Versus -T1/T2.

The study, “No Difference in Reoperation Rates for Adjacent Segment Disease (Operative Adjacent Segment Disease) in Posterior Cervical Fusions Stopping at C7 Versus T1/T2,” is published in the February 01, 2022 issue of the journal Spine.

The retrospective cohort study sought to determine any difference in reoperation rates for adjacent segment disease, operative adjacent segment disease in posterior cervical fusions that stop at –C7 versus –T1/T2.

“There are surgical treatment challenges to the anatomical complexities of the cervicothoracic junction. Current posterior cervical spine surgery is based on the belief that adjacent segment disease occurs if fusions are stopped at C7 although there is varying evidence to support this assumption,” the researchers wrote.

Eight hundred and seventy-five patients with posterior cervical fusions stopping at either -C7 or -T1/T2 were included in the study. They were followed until validated reoperations for adjacent segment disease, membership termination, death, or March 31, 2020.

The researchers reported on descriptive statistics and 5-year crude incidence rates and 95% confidence intervals for operative adjacent segment disease for posterior cervical fusion ending at -C7 or -T1/T2. The average follow-up time was 4.6 years and average time to operative adjacent segment disease was 2.7 (± 2.8) years.

The crude overall incidence rates for stopping at -C7 (2.12% [1.02%-3.86%]) and -T1/T2 (2.48% [1.25%-4.40%]) were comparable with no statistical difference in risk (adjusted hazard ratio = 1.47, 95% confidence interval = 0.61-3.53; p = 0.39). There were also no differences in the probability of operative adjacent segment disease in competing risk time-dependent models (Grey test p = 0.448).

“A large cohort of 875 patients with posterior cervical fusions stopping at -C7 or -T1/T2 with an average follow-up of more than 4 years found no statistical difference in reoperation rates for adjacent segment disease (operative adjacent segment disease),” the researchers wrote.

The study authors included Kern H. Guppy, M.D. of the Permanente Medical Group in Sacrament, CA, Kathryn E. Royse of Surgical Outcomes and Analysis, Kaiser Permanente in San Diego, CA, Jacob Fennessy, M.D. of The Permanente Medical Group, Sacramento, CA, Elizabeth P .Norheim, M.D. of Southern California Permanente Medical Group in Downey, CA, Jessica E. Harris, R.D. of Surgical Outcomes and Analysis, Kaiser Permanente, and Harsimran S. Brara, M.D. of Southern California Permanente Medical Group, Los Angeles, CA.

React:

Discussion

14
DS
Dr. Sarah MitchellOrthopedic Surgeon · Mayo Clinic

This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?

8
JT
James Thornton, MDSpine Fellow · HSS

Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.

5
RP
R. PatelSports Medicine · Stanford

We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.

Join the conversation

Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.

Subscribe

Get Full Access

Read every OTW article and join member discussions for $24.99/month.

Get Full Access

Advertisement

Advertisement

Advertisement

Orthopedics This Week

The most trusted source in orthopedic industry news since 2005. Covering spine, joints, trauma, biologics, and the business of orthopedics.

A publication of RRY Publications, LLC

LinkedInXFacebook

Categories

  • Spine
  • Joints
  • Upper Extremities
  • Foot & Ankle
  • Sports Medicine
  • Pain Mgmt
  • Trauma
  • Biologics
  • Technology
  • People
  • Company News
  • Legal & Regulatory

Resources

  • Subscribe
  • Community Posts
  • Job Board
  • Press Release Opportunities
  • Power Rankings
  • About OTW
  • Advertise
  • Contact Us

Get Full Access

Unlimited articles, community posts, and Power Rankings.

Get Full Access

Plans start at $24.99/mo · Annual saves 20%

© 2026 Orthopedics This Week · RRY Publications, LLC

Privacy PolicyTerms of ServiceCookie Policy